I have 490,000 shares @ current prices and will wait another 12 months with an expectation of a bag or two.
Full Year audited results may not differ from what the market already knows IMO and I apologise, but I don't see any surprises before August. The big news was the acq. of C2B but the market is still at loggerheads over valuations.
I'm usually a resource investor but MBE's growth into 2018 may surprise.
Well done to those who bought cheaper yet as far as the general market goes, MBE may well be a defensive type and for the record, I find it difficult to box this one into an overly speculative type of business from here, despite the register being a basket case and if anything, it will be the market swill that may pop this into the teens if anything for whatever reason.
- Forums
- ASX - By Stock
- IMS
- Why
Why, page-76
-
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online